Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

about

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Item

http://www.wikidata.org/entity/Q59135403

description

article

@en

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Canadian perspectives: update ...... ced non-small-cell lung cancer

@en

Canadian perspectives: update ...... ced non-small-cell lung cancer

@nl

type

Item

label

Canadian perspectives: update ...... ced non-small-cell lung cancer

@en

Canadian perspectives: update ...... ced non-small-cell lung cancer

@nl

prefLabel

Canadian perspectives: update ...... ced non-small-cell lung cancer

@en

Canadian perspectives: update ...... ced non-small-cell lung cancer

@nl

P1476

Canadian perspectives: update ...... ced non-small-cell lung cancer

@en

P2093

A M Y Chan

http://www.w3.org/2001/XMLSchema#string

B Melosky

http://www.w3.org/2001/XMLSchema#string

C Butts

http://www.w3.org/2001/XMLSchema#string

D G Bebb

http://www.w3.org/2001/XMLSchema#string

D N Ionescu

http://www.w3.org/2001/XMLSchema#string

G Liu

http://www.w3.org/2001/XMLSchema#string

J Agulnik

http://www.w3.org/2001/XMLSchema#string

M Tehfe

http://www.w3.org/2001/XMLSchema#string

M Vincent

http://www.w3.org/2001/XMLSchema#string

N Blais

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Molecular pathology of non-small cell lung cancer: a practical guide.

Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

P304

317-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.4379

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ming-Sound Tsao

P577

2018-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30464681

http://www.w3.org/2001/XMLSchema#string

P932

6209554

http://www.w3.org/2001/XMLSchema#string